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New Microbleeds After Thrombolysis
Contiguous Thin-Slice 3T MRI
Shenqiang Yan, MD, Yi Chen, MD, Xuting Zhang, MD, David S. Liebeskind, MD,
and Min Lou, MD, PhD
Abstract: We aimed to determine the frequency of new micro-
bleeds after intravenous thrombolysis using contiguous thin-slice 3T
magnetic resonance imaging. We retrospectively examined clinical
and imaging data from 121 consecutive acute ischemic stroke
patients who underwent magnetic resonance imaging before and
24 hours after intravenous thrombolysis. Of the included patients, 44
(36.4%) were women, with a median age of 69 years (range, 35–
94 years). A total of 363 baseline microbleeds were observed in 57
patients and 8 new microbleeds in 6 patients. Multiple regression
analysis indicated that baseline infarct volume (odds ratio,
1.556/10mL; 95% CI, 1.017–2.379; P¼ 0.04) and systolic blood
pressure (odds ratio, 1.956/10mm Hg; 95% CI, 1.056–3.622;
P¼ 0.03), but not the presence of baseline microbleeds, were
independently associated with new microbleeds. The frequency of
neither symptomatic intracranial hemorrhage nor remote hemorrhage
or any hemorrhagic transformation was different between patients
with and without new microbleeds (0.0% vs 1.7%, P> 0.99; 0.0% vs
1.7%, P> 0.99; 50.0% vs 28.7%, P¼0.36). New microbleeds
developed rapidly 24 hours after intravenous thrombolysis. The
significance of these new microbleeds and their effect on cognitive
and functional outcome merits further investigation.
(Medicine 93(20):e99)
Abbreviations: CMB = cerebral microbleed, DWI = diffusion-
weighted imaging, GRE = gradient-recalled echo, HI = hemor-
rhagic infarction, NIHSS = National Institutes of Health Stroke
Scale, PH = parenchymal hemorrhage, rtPA = recombinant tissue-
type plasminogen activator, sICH = symptomatic intracranial
hemorrhage.
INTRODUCTION
Cerebral microbleeds (CMBs), defined as small, roundedor circular, and hypointense lesions within brain paren-
chyma with clear margins on gradient-recalled echo (GRE)
scans,1 are commonly detected in elderly individuals2 and
patients with cerebrovascular diseases.3 Focal accumulation
of hemosiderin-containing macrophages was noted in areas
with signal loss on magnetic resonance imaging (MRI).4
CMBs might be a potential risk factor for intracranial
hemorrhage (ICH) after ischemic stroke,5 or after thromboly-
sis.6,7 Generally, CMBs have been considered to be old
microhemorrhages that develop over an individual’s lifetime,4
but recent studies indicated that CMBs might develop rapidly
after acute ischemic stroke8 or after tissue-type plasminogen
activator infusion.9 It is increasingly known that the presence,
number, and size of CMBs may vary substantially with the
parameters of GRE. Longer echo time (TE) (range, 25–50ms),
higher spatial resolution (3-dimensional [3D] Fourier transform
technique, thinner scanning sections, and no interslice gap),
and increased field strength can increase the sensitivity of
CMBs detection.1 However, the GRE sequences used in these
2 studies had a relatively greater slice thickness (5-mm and 6-
mm) and interslice gap (2-mm and 1-mm) and were performed
on 1.5T MRI.8,9 We therefore deemed it worthy to detect the
CMBs with a contiguous, thin-slice, and 3D multiecho GRE
sequence performed with a 3T MRI unit. Based on such
measurements, this study aims to delve into the variations in
GRE characteristics and their influence on detecting new
CMBs, and investigate the independent risk factors of new
CMBs and the relationship between new CMBs and ICH after
thrombolysis.
MATERIALS AND METHODS
Study Subjects
We retrospectively reviewed our prospectively collected
database for consecutive patients with acute ischemic stroke
who received thrombolytic therapy between June 2009 and
September 2013. We then enrolled patients who had a
diagnosis of acute ischemic stroke confirmed by diffusion-
weighted imaging (DWI), received intravenous recombinant
tissue-type plasminogen activator (rtPA) within 6 hours of
symptom onset, underwent GRE sequence before rtPA
infusion, and underwent follow-up GRE sequence 24 hours
after rtPA infusion. The onset was considered to be the time
when a patient was last known to be without ischemic
symptoms. We excluded patients whose image quality was
poor because of motion artifacts. No patient received
antithrombotic agents within 24 hours after rtPA infusion.
We retrieved demographic, clinical, laboratory, and imag-
ing data including age and sex; comorbid conditions such as
history of hypertension, diabetes mellitus, hyperlipidemia,
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atrial fibrillation, and hyperhomocysteinemia; previous use of
aspirin and warfarin; time interval from stroke onset to rtPA
infusion; National Institutes of Health Stroke Scale (NIHSS)
score,10 systolic blood pressure (SBP), diastolic blood pressure
(DBP), serum glucose, serum creatinine, platelet and interna-
tional normalized ratio (INR) before rtPA infusion; infarct
volume before rtPA infusion, leukoaraiosis volume, presence
of baseline and new CMBs, number of baseline and new
CMBs, hemorrhagic transformation 24 hours after rtPA
infusion, and modified Rankin Scale (mRS) score after
3 months.11 The follow-up MRI was done before any subject
was started on antithrombotic therapy.
Ethics Statement
All subjects conducting the research project in this
manuscript had given written informed consent prior to the
study and the protocols of MRI-guided intravenous thrombo-
lysis had been approved by the human ethics committee of
the Second Affiliated Hospital of Zhejiang University School
of Medicine.
MRI Parameters
All subjects underwent MRI on a 3.0T system (Signa
Excite HD; General Electric Medical System, Milwaukee,
WI). The 3D multiecho GRE sequence covered the whole
brain and used 11 equally spaced echoes: TE¼ 4.5ms
(first echo), interecho spacing¼ 4.5ms, repetition time (TR)
¼ 58ms, field of view (FOV)¼ 24 24 cm2, matrix size
¼ 256 256, flip angle¼ 20°, slice thickness¼ 2.0mm with
no gap between slices, and in-plane spatial resolution of
0.4688 0.4688mm/pixel. Magnitude images were acquired.
Axial T2 fluid-attenuated inversion recovery sequence was
used to measure the leukoaraiosis volume (TR¼ 10,000ms,
TE¼ 150ms, FOV¼ 24 24 cm2, matrix size¼ 256 256,
inversion time¼ 2500ms, slice thickness¼ 5.0mm with no
gap between slices, and in-plane spatial resolution of
0.4688 0.4688mm/pixel). DWI sequence was used to
measure the infarct volume before rtPA infusion
(TR ¼ 4000ms, TE¼ 69.3ms, b-value¼ 1000 s/mm2 with 3
acquired diffusion directions, FOV¼ 24 24 cm2, matrix
size¼ 160 160, slice thickness¼ 5.0mm, interslice gap
¼ 1.0mm, and in-plane spatial resolution of
0.9375 0.9375mm/pixel); the segmentation threshold for
infarct lesion was determined a priori as 3 standard
deviations in pixel intensity above the mean of the fitted
distribution of the contralateral brain parenchyma.
Detection Criteria of Baseline and New CMBs
We identified a CMB according to a field guide for the
detection and interpretation of CMBs.1 Briefly, the signal of
a CMB should be black or very hypointense on T2*-
weighted MRI, round or ovoid with a size of 10mm,
blooming, devoid of T1- or T2-weighted hyperintensity, and
at least half-surrounded by brain parenchyma. Mineralization
of the basal ganglia and diffuse axonal injury are excluded
based on appearance or clinical history.
New CMBs were defined as CMBs that newly appeared on
the follow-up GRE scans compared with the initial scans. We
described the locations, counted the number of all CMBs on
baseline and follow-up GRE scans independently, and then
performed slice-to-slice comparison to determine whether the
CMBs on follow-up GRE scans were new or unchanged. DWI
was used to confirm that the new CMBs occurred outside the
infarct area. Newly appearing CMBs in the acute infarct area
were not regarded as new CMBs. CMBs that were questionably
hypointense on the initial GRE scans but became conspicuous
on the follow-up were not regarded as new CMBs. The locations
of CMBs were classified as lobar, deep, or infratentorial.8
Evaluation of Outcome
Hemorrhagic transformation was classified by using
clinical and imaging criteria as follows: hemorrhagic infarc-
tion (HI), parenchymal hemorrhage (PH), extraischemic
hemorrhage, and symptomatic ICH (sICH). An ICH was
defined as sICH if the patient had clinical deterioration
causing an increase of NIHSS ³4 points and if the
hemorrhage was likely to be the cause of the clinical
deterioration.12 An extraischemic hemorrhage was defined as
the new appearance of hypointense lesions with a diameter
of >10mm outside the infarct area on follow-up GRE scans
and at least 1 aspect didn’t meet the detection criteria of
CMBs. Outcome was dichotomized into good clinical
outcome (mRS, 0–2) or poor clinical outcome (mRS, 3–6) at
3 months.
Reliability and Validity of the Radiological Data
Two investigators blinded to the patients’ clinical data
jointly evaluated the MRI findings. A trained observer (S.Y.)
evaluated the images of all patients twice, at an interval of
3 months. Another observer (M.L.) independently made the
same evaluation. The interobserver intraclass correlation
coefficients (ICCs) were 0.96 and 0.95 for the number of
baseline and new CMBs, respectively. The intraobserver
ICCs were 0.93 and 0.94 for the number of baseline and new
CMBs, respectively. ICCs were described in detail else-
where.13 The interobserver and intraobserver reliabilities
about the presence of CMBs (³1) were also acceptable (κ
value¼ 0.86 and 0.81, respectively). Discrepancies were
resolved by consensus.
Statistical Analysis
Fisher exact test was used to compare the dichotomous
variables between groups, whereas independent samples of
2-tailed t test or Mann–Whitney U test was used for
continuous variables. Variables with a P< 0.10 in univariate
regression analyses were included in the binary logistic
regression model, whereas NIHSS score before rtPA infu-
sion, time from onset to treatment, previous use of aspirin or
warfarin, infarct volume before rtPA infusion, which were
thought to be potential factors associated with ICH after
intravenous thrombolysis, and age, hyperhomocysteinemia,
presence of baseline CMBs, leukoaraiosis volume, which
were thought to be associated with small vessel disease, were
forced into the model. Hosmer–Lemeshow test was used to
evaluate the difference between observed and predicted event
rates in the binary logistic regression model. Statistical
significance was set at a probability value of <0.05. All
statistical analysis was performed with SPSS package (14.0
for Windows; SPSS Inc, Chicago, IL).
RESULTS
A total of 167 consecutive patients with acute ischemic
stroke received MRI-guided intravenous thrombolysis during
the study period. Among them, 39 did not undergo follow-up
MRI 24 hours after treatment, MRI quality was poor for
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analysis in 4, and 3 had hypointense lesion on GRE scans
with suspicious cavernous malformations, which might affect
CMBs evaluation. A total of 121 remaining patients were
included for the final analysis. Demographic, clinical, and
laboratory data were not different between included and
excluded subjects, except that baseline NIHSS score was
higher in excluded patients (13.3 6.7 vs 9.5 5.9), mainly
because some severe stroke patients were transferred to
intensive care unit or received surgical treatment, resulting in
failure of follow-up GRE scans. Of the included patients, 44
(36.4%) were women, with a median age of 69 years (mean,
67.26 12.53 years; range, 35–94 years).
On initial GRE scans, we observed 363 CMBs in 57
patients (47.1%). The median number of baseline CMBs was
2 (range, 1–65). On follow-up GRE scans 24 hours after
treatment, 8 new CMBs in 6 patients (5.0%) were observed.
The median number of new CMBs among these patients was
1 (range, 1–2). None of the baseline CMBs disappeared on
follow-up GRE scans. New CMBs were found in 5 (7.8%) of
64 patients without baseline CMBs, 0 (0.0%) of 36 patients
with baseline CMBs of 1 to 2, and 1 (4.8%) of 21 patients
with microbleeds of >2 (Fisher exact test, P¼ 0.25).
There were 133 (36.6%) baseline CMBs in a lobar
location, 178 (49.0%) in a deep location, and 52 (14.3%) in
an infratentorial location. For the 8 new CMBs, 4 (50.0%)
were lobar, 2 (25.0%) were deep, 2 (25.0%) were infra-
tentorial, and 6 new CMBs were located in the ipsilateral
hemisphere of infarction, whereas 2 were in the contralateral
hemisphere. Among 57 patients with baseline CMBs, 13 had
lobar CMBs, 15 had deep CMBs, 1 had infratentorial CMBs,
14 had lobar and deep CMBs, 2 had lobar and infratentorial
CMBs, 1 had deep and infratentorial CMBs, and 11 had
lobar, deep, and infratentorial CMBs. In addition, 11 patients
had multiple baseline CMBs (>2) in the lobar location.
Table 1 shows the characteristics of patients with and
without new CMBs for comparison. There were no signifi-
cant differences in the risk factors between patients with and
without new CMBs in univariate analysis. Only increased
SBP and INR were marginally associated with new CMBs.
Patients with baseline CMBs didn’t have more new CMBs
than those without baseline CMBs (1.8% vs 7.8%, P¼ 0.21).
Age, hyperhomocysteinemia, the presence of baseline
CMBs, baseline NIHSS, time from onset to treatment, previous
use of aspirin or warfarin, baseline infarct volume and
leukoaraiosis volume, SBP, and INR were included in the
binary logistic regression model. Baseline DWI infarct volume
and SBP were the independent factors associated with new
CMBs (Table 2). The Hosmer–Lemeshow test showed no
significant difference (P¼ 0.99) between observed and pre-
dicted event rates.
Follow-up GRE scans 24 hours after treatment revealed
hemorrhagic transformation in 36 (29.8%, 28 were HI and 8
were PH) patients, and sICH was observed in 2 (1.7%)
patients. Two (1.7%) patients had remote hemorrhage, one of
which had sICH. The frequency of sICH (0.0% vs 1.7%,
P> 0.99) or remote hemorrhage (0.0% vs 1.7%, P> 0.99) or
any hemorrhagic transformation (50.0% vs 28.7%, P¼ 0.36)
was not different between patients with and without new
CMBs. Patients with baseline multiple lobar CMBs (>2) also
did not reveal higher risk of sICH (0.0% vs 1.8%, P> 0.99),
remote hemorrhage (0.0% vs 1.8%, P> 0.99), or any
hemorrhagic transformation (9.1% vs 31.8%, P¼ 0.17). The
presence of new CMBs was not associated with poor clinical
outcome after adjusting for baseline NIHSS score and age in
the binary logistic regression model (odds ratio, 0.557; 95%
CI, 0.072–4.286; P¼ 0.57).
DISCUSSION
In the current study, we found that new CMBs
developed rapidly in 5.0% of acute ischemic stroke patients
received intravenous thrombolysis. However, the occurrence
of new CMBs was not independently related with the
presence of baseline CMBs, and patients with new CMBs
TABLE 1. Univariate Comparison of Characteristics Between
Patients With and Without New CMBs
New CMBs
Variable
With
(n¼ 6)
Without
(n¼ 115) P Value
Age, y 72.17 12.92 67.01 12.51 0.33
Women 2 (33.3%) 42 (36.5%) >0.99
Past medical history
Hypertension 6 (100%) 78 (67.8%) 0.18
Diabetes mellitus 1 (16.7%) 22 (19.1%) >0.99
Hyperlipidemia 0 (0.0%) 6 (5.2%) >0.99
Atrial fibrillation 2 (33.3%) 40 (34.8%) >0.99
Hyperhomo-
cysteinemia
2 (33.3%) 34 (29.6%) >0.99
Clinical variables
NIHSS score 9.00 7.35 9.56 5.90 0.82
Onset to treatment,
min
200.00 43.00 242.43 78.44 0.19
Previous use of
aspirin or warfarin
1 (16.7%) 14 (12.2%) 0.56
SBP, mm Hg 172.67 18.06 155.74 23.71 0.09
DBP, mm Hg 85.67 18.60 86.78 14.23 0.85
Glucose, mmol/L 7.66 3.67 7.86 2.94 0.87
Creatinine,
μmmol/L
74.33 15.15 71.81 16.65 0.72
Platelet (109/L) 187.33 44.86 185.62 60.73 0.95
INR 1.10 0.11 1.04 0.08 0.08
Radiological data
Baseline infarct
volume, mL
26.1 51.8 11.4 26.2 0.57*
Leukoaraiosis
volume, mL
15.94 15.75 11.01 11.52 0.37*
Presence of
baseline CMBs
1 (16.7%) 56 (48.7%) 0.21
Number of
baseline CMBs
0.50 1.23 3.13 9.15 0.19*
Hemorrhagic
transformation
0.36
HI 2 (33.3%) 26 (22.6%)
PH 1 (16.7%) 7 (6.1%)
sICH 0 (0.0%) 2 (1.7%) >0.99
Extraischemic
hemorrhage
0 (0.0%) 2 (1.7%) >0.99
CMBs¼ cerebral microbleeds, DBP¼ diastolic blood pressure,
HI¼ hemorrhagic infarction, INR¼ international normalized ratio,
NIHSS¼National Institutes of Health Stroke Scale, PH¼ paren-
chymal hemorrhage, SBP¼ systolic blood pressure, sICH¼ symp-
tomatic intracranial hemorrhage.
*Mann–Whitney U test.
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did not experience more hemorrhagic transformation than
those without new CMBs.
Generally, CMBs are regarded as old microhemorrhage
and follow a slow process of development because histo-
pathological analysis shows that CMBs consist of hemo-
siderin accumulations from red blood cells that presumably
have leaked out of small vessels.4 However, a recent
systematic review report stated that 12.9% of CMBs
contained erythrocytes rather than hemosiderin, which indi-
cated that not all CMBs are chronic in nature.14 Indeed, Jeon
et al8 reported that 12.7% of acute ischemic stroke patients
developed new CMBs within 1 week of stroke onset,
whereas Kimura et al9 reported that 4.9% of acute ischemic
stroke patients developed new CMBs 24 hours after rtPA
infusion. Our results are similar to the findings of Kimura
et al9 and confirm that CMBs could occur in the acute stage
of ischemic stroke.
However, our findings did not repeat the previous findings
that the presence of CMBs before rtPA therapy was associated
with new CMBs. When we reviewed and compared the
parameters of GRE scans in different studies (Table 3),
including field strength, echo time, slice thickness, and
interslice gap, we found that new CMBs may be misidentified
even though slice-to-slice comparison between initial and
follow-up GRE scans was done. Usually, CMB detection
depends on lesion size, slice thickness, lesion position relative
to slice, thickness of gap between slices, and inherent contrast
between lesion and background.15 Image co-registration is not
reliable with a relatively greater slice thickness and an
interslice gap. As shown in Figure 1, if there is an interslice
gap in the GRE protocol, the unchanged CMBs may be
undetected or misidentified as “new” or “disappeared” CMBs
because of even a minor head motion. The images of our
patient with initial and follow-up GRE scans presented in
Figure 2 further confirm this misidentification. Thus, the
misidentified “new” CMBs would only appear in the patients
with baseline CMBs, which leads to the bias that more “new”
CMBs occurred in the patients with the presence of CMBs.
Similarly, this reason could also explain the phenomenon that
8 baseline CMBs in 7 patients were disappeared on follow-up
GRE scans in the study by Jeon et al.8 Furthermore, radiologi-
cal size of the missed CMBs might be larger than the thickness
of interslice gap (such as 1- or 2-mm) because of the so-called
“blooming” effect.1 Therefore, a contiguous thin-slice imaging
study is particularly important in determining whether a CMB
is new or not. Our study, the first to use contiguous 2-mm
slice-to-slice comparison to detect CMBs, confirms that the
presence of baseline CMBs is not a predictor for the
development of new CMBs after thrombolytic therapy.
We found that large baseline DWI infarct volume and
high SBP were the independent factors associated with new
CMBs. The cellular mechanism that underlies the formation
of new CMBs remains to be elucidated. It is suggested that
CMBs result from 2 main pathogenic mechanisms: leakage
from damaged vessels in cerebral small vessel diseases
associated with hypertension and other cerebrovascular risk
factors, or from vessels damaged by vascular amyloid
deposition. “New” CMBs have been reported to occur in
38% of patients with cerebral amyloid angiopathy and
previous lobar hemorrhage during the 1.5-year follow-up
period16 and in 30% of hypertensive patients with ICH after
a median period of 23 months.17 New CMBs appearing
TABLE 2. Multivariate Logistic Regression Analysis of Risk
Factors for New CMBs
Odds Ratio 95% CI P Value
Age, y 1.086 0.950–1.242 0.23
Hyperhomocysteinemia 2.361 0.150–37.127 0.54
Presence of baseline CMBs 0.029 0.001–1.143 0.06
NIHSS score 0.843 0.625–1.136 0.26
Onset to treatment, min 0.988 0.970–1.007 0.21
Previous use of aspirin or
warfarin
0.679 0.031–14.638 0.81
Baseline infarct
volume/10mL
1.556 1.017–2.379 0.04*
Leukoaraiosis
volume/10mL
1.523 0.455–5.098 0.50
SBP/10mm Hg 1.956 1.056–3.622 0.03*
INR/0.1 4.712 0.952–23.316 0.06
CI¼ confidence interval, CMBs¼ cerebral microbleeds, INR¼ inter-
national normalized ratio, NIHSS¼National Institutes of Health Stroke
Scale, SBP¼ systolic blood pressure.
*P< 0.05.
TABLE 3. Clinical Studies Investigating New CMBs in Acute Ischemic Stroke Patients
Study Jeon et al8 Kimura et al9 Current Study
Population Stroke patients Stroke patients treated with tPA Stroke patients treated with rtPA
Number of participants 237 224 121
Age, y 64.0 12.8 76.2 10.6 67.3 12.6
Parameters of GRE scans
Field strength, tesla 1.5 1.5 3.0
Echo time, ms 30 20 11 echoes, first 4.5; interecho spacing 4.5
Slice thickness, mm 5 6 2
Interslice gap, mm 2 1 0
CMBs
Baseline prevalence 31.6% 32.1% 47.1%
New prevalence 12.7% 4.9% 5.0%
Disappeared 8 Not reported 0
CMBs¼ cerebral microbleeds, GRE¼ gradient-recalled echo, rtPA¼ recombinant tissue-type plasminogen activator, tPA¼ tissue-type
plasminogen activator.
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within 24 hours after rtPA treatment would be fresh. Hence,
the presence of large DWI infarct volume in the acute
ischemic stage may precipitate abnormal permeability of the
arteriolar blood–brain barrier leading to extravasation of
blood components, providing a possible explanation for its
association with the formation of new CMBs. Previous
studies showed blood pressure elevation was associated with
hemorrhagic transformation in patients with rtPA therapy.
The arterioles are vulnerable to the effects of high blood
pressure, resulting in damage to the smooth muscle cells and
microbleeding. Thus, blood pressure lowering treatment
during rtPA infusion should be important to reduce the
occurrence of new CMBs.
It has been questioned whether the presence of microbleeds
is a risk factor for sICH after tPA therapy. However, it was
underpowered to detect the relationship between CMBs and
sICH in our study due to the small number of sICH patients. We
did not find the difference between patients with and without
new CMBs in the frequency of hemorrhagic transformation both
in the infarct and extraischemic area, which is inconsistent with
the previous finding that extraischemic hemorrhage was associ-
ated with new CMBs.9 Indeed, it was difficult to discriminate
new CMBs from extraischemic hemorrhage sometimes. Micro-
bleeds and macrobleeds may fall in a naturally bimodal size
distribution that does not strongly depend on the precise cut
point chosen to differentiate them. The size of a CMB is
relatively less important for correctly categorizing lesions
because it depends on imaging parameters on MRI.1 Further-
more, the presence of new CMBs may have little clinical
implication in the prevention of hemorrhagic transformation
after thrombolysis, considering that new CMBs and hemorrhagic
transformation are both detected on follow-up imaging scans.
The present study had limitations. First, our study had a
retrospective design and might have a potential risk of
selection bias. Some severe stroke patients might transfer to
intensive care unit or receive surgical treatment next day so
that they were unable to undergo follow-up GRE scans,
leading to the small sample of patients with sICH. Second,
some new CMBs outside the infarct area might be covered
by remote hemorrhage. This limitation made it more difficult
to detect new CMBs and investigate the relationship between
new CMBs and postthrombolytic hemorrhage. Third, inter-
slice gap has been used sometimes to minimize interference
from adjacent slices (“cross-talk”), which is a cause of
reduced signal intensity, so we used a 3.0 tesla field strength
magnet to provide a high signal-to-noise ratio and high
spectral resolution, in order to minimize this limitation.18
Fourth, we did not perform follow-up computed tomography
(CT) scans, which might discriminate new CMBs from tiny
remote hemorrhage after rtPA infusion.
In summary, we found that new CMBs developed in 5% of
thrombolytic patients. The baseline DWI infarct volume and
SBP, but not the presence of baseline CMBs, were independent
factors associated with new CMBs. We highlight the effect of
variation in slice thickness and interslice gap on new CMB
detection. It is still uncertain whether the new CMBs are caused
by thrombolysis or just ischemic stroke. The significance of
FIGURE 1. Theoretical illustration of new CMB detection. (a), (b), (c), and (d) represent unchanged CMBs on the initial (A) and
follow-up (B) GRE scans. The space between green lines is scan slice, and blue is interslice gap. Therefore, (b) and (c) are observed
on initial scans, and (a) and (b) are observed on follow-up scans. At last (a), (b), (c), and (d) are identified as “new” CMB,
unchanged CMB, “disappeared” CMB, and undetected CMB, respectively. CMB¼ cerebral microbleed, GRE¼gradient-recalled
echo.
FIGURE 2. Initial and follow-up GRE scans of an acute ischemic
stroke patient. (A), (B), and (C) were the 28th, 29th, and 30th
slice before rtPA infusion, respectively. (D), (E), and (F) were
the 28th, 30th, and 31st slice 24 hours after rtPA infusion,
respectively. A “new” CMB shown in slice-to-slice comparison
between (A) and (D) (the 28th slice, red arrow) could be
observed on the 29th but not the 30th slice of the initial GRE
scans. If (B) (the 29th slice) was in an interslice gap, the CMB
in red arrow would be misidentified as “new” CMB; a
“disappeared” CMB showed in slice-to-slice comparison
between (C) and (E) (the 30th slice, blue arrow) could be
observed on the 31st slice of the follow-up GRE scans. If (F) the
31st slice was in an interslice gap, the CMB in blue arrow
would be misidentified as “disappeared” CMB. CMB¼ cerebral
microbleed, GRE¼gradient-recalled echo, rtPA¼ recombinant
tissue-type plasminogen activator.
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these new CMBs and their effect on cognitive and functional
outcome requires further investigations.
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